Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy

Structural Heart Interventions and Periprocedural Anticoagulation

Research activity includes anticoagulation management around transseptal structural procedures, with attention to Transcatheter Edge-to-Edge Repair and Left Atrial Appendage Closure. The focus is on balancing thromboembolic protection and bleeding risk in patients undergoing invasive cardiac intervention.

  • Transseptal cardiac procedures
  • Anticoagulant therapy
  • Stroke prevention
  • Bleeding risk management

Additional interest extends to antiplatelet strategies after left atrial appendage closure in patients with complex cardiovascular comorbidity.

Coronary Artery Disease, Atherosclerosis, and Prediabetes

Clinical research covers coronary disease linked with metabolic risk, including coronary atherosclerosis and prediabetes. The therapeutic landscape centers on cardiovascular risk reduction and plaque-related disease progression.

  • Coronary artery disease
  • Coronary atherosclerosis
  • Metabolic cardiology
  • Anti-atherosclerotic treatment

Interest also includes oral glucose-lowering therapies with cardiovascular relevance, especially in relation to coronary plaque burden assessed over time.

Hypertrophic Cardiomyopathy and Atrial Fibrillation

A major area of focus is hypertrophic cardiomyopathy, particularly when complicated by atrial fibrillation and reduced functional capacity. The research portfolio addresses rhythm control, arrhythmia prevention, and exercise limitation in this inherited cardiac condition.

  • Atrial fibrillation prevention
  • Rhythm control strategies
  • Exercise capacity
  • Inherited cardiomyopathy

There is also interest in therapies aimed at maintaining sinus rhythm and limiting arrhythmic complications in patients with structural heart disease.

Fontan Circulation and Congenital Heart Disease

Research includes adults with functionally single ventricle physiology after Fontan operation, where the emphasis is on circulatory support and physical performance. This area reflects ongoing work in complex congenital heart disease.

  • Fontan circulation
  • Single ventricle physiology
  • Exercise intolerance
  • Pulmonary vascular resistance

Therapeutic interest also includes hemodynamic optimization in patients living with long-term consequences of congenital cardiac surgery.

Hypertension, Antiplatelet Therapy, and Arrhythmogenic Cardiomyopathy

The sponsor also studies difficult-to-treat hypertension, antiplatelet management in high-risk cardiovascular patients, and disease-modifying approaches in arrhythmogenic cardiomyopathy. These topics reflect a broad interest in vascular control, thrombosis prevention, and myocardial remodeling.

  • Resistant hypertension
  • Dual and single antiplatelet therapy
  • Arrhythmogenic cardiomyopathy
  • Cardiac remodeling

Related work includes treatment pathways for patients with renal impairment who require long-term cardiovascular antithrombotic care.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of Optimal Treatment for Uncontrolled Hypertension Using Triple Drug Combinations (Olmesartan/Amlodipine/Hydrochlorothiazide or Perindopril/Indapamide/Amlodipine) with Additional Diuretics

    Recruiting

    1 1 1
    Investigated diseases:
    Poland
  • Study on Sildenafil for Adults with Single Ventricle Heart Condition Post-Fontan Surgery

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland
  • Study on Valsartan and Sacubitril for Preventing Disease Progression in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland
  • Study on the Effects of Semaglutide, Dapagliflozin, and Metformin in Patients with Coronary Artery Disease and Prediabetes

    Recruiting

    1 1 1 1
    Investigated diseases:
    Poland
  • Study of acetylsalicylic acid and clopidogrel treatment duration after left atrial appendage closure in patients with atrial fibrillation

    Not yet recruiting

    1 1 1 1 1
    Investigated diseases:
    Poland
  • Title: Evaluation of optimal timing for heparin anticoagulation in patients undergoing transseptal heart procedures (TEER or left atrial appendage closure)

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland